Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 98.45% is in line with its 3-year average of 100.00%, around the middle of its 3-year range (95.26%–100.00%).
0.61% below its 12-month average of 99.05%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
98.45%
GROSS MARGIN AVG TTM
99.05%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.61%
CURRENT VS 3Y AVG
-1.55%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+137.92%
vs the sector median at left
Market Cap
$248.50M
Gross Margin
53.14%
TTM Avg
76.57%
3Y Avg
72.53%
5Y Avg
61.83%
Market Cap
$247.62M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$247.27M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
18.35%
5Y Avg
-18.33%
Market Cap
$255.88M
Gross Margin
62.16%
TTM Avg
59.97%
3Y Avg
63.15%
5Y Avg
60.27%
Market Cap
$256.47M
Gross Margin
100.00%
TTM Avg
-14.56%
3Y Avg
-49.51%
5Y Avg
-80.59%
Market Cap
$241.94M
Gross Margin
N/A
TTM Avg
31.32%
3Y Avg
30.59%
5Y Avg
32.68%
Market Cap
$241.34M
Gross Margin
47.33%
TTM Avg
49.83%
3Y Avg
36.19%
5Y Avg
24.13%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Upstream Bio, Inc. (UPB) | $249.79M | 98.45% | 99.05% | 100.00% | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $248.50M | 53.14% | 76.57% | 72.53% | 61.83% |
| Galectin Therapeutics Inc. (GALT)vs › | $247.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.27M | 100.00% | 100.00% | 18.35% | -18.33% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | 62.16% | 59.97% | 63.15% | 60.27% |
| AC Immune S.A. (ACIU)vs › | $256.47M | 100.00% | -14.56% | -49.51% | -80.59% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | 31.32% | 30.59% | 32.68% |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | 99.84% | 50.00% | 75.00% | 50.00% |
| Quantum-Si incorporated (QSI)vs › | $241.34M | 47.33% | 49.83% | 36.19% | 24.13% |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | 0.00% | 0.00% | 25.00% | 16.67% |
Gross Margin
98.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 95.26% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
